Seqirus, Maidenhead, UK.
Medialis Ltd, Banbury, UK.
Vaccine. 2020 Aug 27;38(38):6047-6056. doi: 10.1016/j.vaccine.2020.06.021. Epub 2020 Jun 26.
Influenza is associated with significant morbidity and mortality worldwide. Whilst vaccination is key for the prevention of influenza infection, there are many factors which may contribute to reduced vaccine effectiveness, including antigenic evolution via both antigenic drift and egg-adaptations. Due to the currently dissociated and indirect evidence supporting both the occurrence of these two phenomena in the egg-based manufacturing process and their effects on vaccine effectiveness, this topic remains a subject of debate.
To review the evidence and level of agreement in expert opinion supporting a mechanistic basis for reduced vaccine effectiveness due to egg-based manufacturing, using an expert consensus-based methodology and literature reviews.
Ten European influenza specialists were recruited to the expert panel. The overall research question was deconstructed into four component principles, which were examined in series using a novel, online, two-stage assessment of proportional group awareness and consensus. The first stage independently generated a list of supporting references for each component principle via literature searches and expert assessments. In the second stage, a summary of each reference was circulated amongst the experts, who rated their agreement that each reference supported the component principle on a 5-point Likert scale. Finally, the panel were asked if they agreed that, as a whole, the evidence supported a mechanistic basis for reduced vaccine effectiveness due to egg-based manufacturing.
All component principles were reported to have a majority of strong or very strong supporting evidence (70-90%).
On reviewing the evidence for all component principles, experts unanimously agreed that there is a mechanistic basis for reduced vaccine effectiveness resulting from candidate influenza virus variation due to egg-based manufacturing, particularly in the influenza A/H3N2 strain. Experts pointed to surveillance, candidate vaccine virus selection and manufacturing stages involving eggs as the most likely to impact vaccine effectiveness.
流感在全球范围内可导致严重的发病率和死亡率。虽然疫苗接种是预防流感感染的关键,但有许多因素可能会降低疫苗的有效性,包括通过抗原漂移和鸡蛋适应而发生的抗原进化。由于目前支持这两种现象在基于鸡蛋的制造过程中发生及其对疫苗有效性影响的证据是分离的和间接的,因此这个话题仍然存在争议。
使用基于专家共识的方法和文献综述,回顾由于基于鸡蛋的制造而导致疫苗有效性降低的证据和专家意见的一致性水平,探讨其机制基础。
招募了 10 名欧洲流感专家组成专家小组。将总体研究问题分解为四个组成原则,然后使用新颖的在线两阶段评估比例组意识和共识,依次检查这些原则。第一阶段通过文献搜索和专家评估,独立为每个组成原则生成了一份支持性参考文献列表。在第二阶段,将每份参考文献的摘要分发给专家,专家们对每一份参考文献支持组成原则的程度进行 5 分制的评分。最后,专家小组被问到他们是否同意,总的来说,证据支持由于基于鸡蛋的制造而导致疫苗有效性降低的机制基础。
所有组成原则都报告了大部分强有力或非常有力的支持证据(70-90%)。
在审查所有组成原则的证据后,专家们一致认为,由于基于鸡蛋的制造导致候选流感病毒变异,疫苗有效性降低存在机制基础,特别是在甲型 H3N2 株中。专家们指出,监测、候选疫苗病毒选择和涉及鸡蛋的制造阶段最有可能影响疫苗的有效性。